TABLE 1.

Characteristics of patients according to outcome

Characteristic	Value for patients with treatment:		Pb
	Failure (n = 12)a	Remission (n = 35)
Median (IQR) age (yr)	71 (64.2-79)	75 (63-79)	0.96
No. (%) female	7 (58.3)	24 (68.3)	0.37
No. (%) of patients with a comorbidityc	6 (50)	15 (42.9)	0.46
No. (%) of patients with the following type of prosthesis:
Hip	4 (33.5)	11 (31.4)
Knee	8 (66.7)	24 (68.6)	0.58
Median (IQR) age of prosthesis (days)	19 (17.2-22.7)	21 (13-31)	0.71
No. (%) of patients with the following type of infection:
Postsurgical	12	32 (91.4)
Hematogenous	0	3 (8.6)	0.40
Median (IQR) leukocyte count (no. of cells/mm3)	8,750 (4,925-11,122)	8,100 (6,150-10,417)	0.97
Median (IQR) CRP concn (mg/dl)	11.4 (1.4-21.4)	4.2 (0.8-12.9)	0.20
No. (%) of patients with:
CRP concn of >15 mg/dl	6 (50)	6 (17.1)	0.03
Bacteremia	0	4 (11.4)	0.29
Polymicrobial infection	7 (58.3)	21 (60)	0.59
Mixed infection with gram-positive organisms	3 (25)	15 (42.9)	0.32
Infection due to a Pseudomonas sp.d	4 (33.5)	16 (45.7)	0.34
Infection due to a fluoroquinolone-resistant strain	8 (66.7)	5 (14.3)	0.001
Infection due to an ESBL-producing member of Enterobacteriaceae family	4 (33.3)	4 (11.4)	0.17
Need for a second debridement	3 (25)	4 (11.4)	0.24
Median (IQR) duration of antibiotic therapy (oral and intravenous) (days)	84.5 (35.5-167.2)	82 (47-135)	0.94
Median (IQR) duration of oral antibiotic therapy (days)e	95 (27.7-165.2)	64 (36-101.5)	0.46
No. (%) of patients treated with fluoroquinolones	7 (58.3)	28 (80)	0.13
No. (%) of patients treated with fluoroquinolones when all isolated GNB were susceptible	2 (16.7)	26 (74.3)	0.001

^aIncluding relapse and reinfection.

^bMann-Whitney U test, χ² test, or Fisher exact test, when necessary.

^cDiabetes mellitus, liver cirrhosis, chronic renal failure, rheumatoid arthritis, or chronic obstructive pulmonary disease.

^dP. aeruginosa in 19 cases and Pseudomonas stutzeri in 1 case.

^eThe information is for those patients who received oral antibiotics (n = 41).